Restenosis after PCI. Part 2: Prevention and therapy

Nature Reviews Cardiology

Volumn 9, Issue 2, 2012, Pages 79-90

  Jukema, J Wouter ^a   Ahmed, Tarek A N ^a   Verschuren, Jeffrey J W ^a   Quax, Paul H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOY; ANTITHROMBOCYTIC AGENT; CHROMIUM; CILOSTAZOL; EVEROLIMUS; MAGNETIC NANOPARTICLE; METAL OXIDE; NANOPARTICLE; NOVOLIMUS; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE III INHIBITOR; PIOGLITAZONE; PLASMID DNA; PLATINUM; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; ROSIGLITAZONE; TITANIUM; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADD ON THERAPY; ADENOVIRUS; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABILITY; BLEEDING; BRACHYTHERAPY; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE APPROVAL; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; ENDOTHELIAL PROGENITOR CELL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GENE DELIVERY SYSTEM; GENE ELUTING STENTT; HEADACHE; HEART PALPITATION; HUMAN; IN-STENT RESTENOSIS; MAGNETIC FIELD; MAGNETIC TARGETING STENT; MATERIAL COATING; MEDICAL TECHNOLOGY; NANOMEDICINE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMID; PRIORITY JOURNAL; RESTENOSIS; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; NANOPARTICLES; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 84856238292     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.148     Document Type: Review

References (142)

1. Gruntzig, A. R., Senning, A. & Siegenthaler, W. E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301, 61-68 (1979). (Pubitemid 9229695)
2. Agema, W. R., Jukema, J. W., Pimstone, S. N. & Kastelein, J. J. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur. Heart J. 22, 2058-2074 (2001). (Pubitemid 33091449)
3. Regar, E. et al. Angiographic findings of the multicenter Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106, 1949-1956 (2002). (Pubitemid 35176300)
4. Simsek, C. et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. JACC Cardiovasc. Interv. 3, 1051-1058 (2010).
5. Stolker, J. M. et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ. Cardiovasc. Interv. 3, 327-334 (2010).
6. Jukema, J. W., Verschuren, J. J., Ahmed, T. A. & Quax, P. H. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2011.132.
7. Stettler, C. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370, 937-948 (2007). (Pubitemid 47393576)
8. Daemen, J. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667-678 (2007). (Pubitemid 46281313)
9. Hassan, A. K. et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur. Heart J. 31, 1172-1180 (2010).
10. Cook, S. et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120, 391-399 (2009).
11. Pires, N. M., Eefting, D., de Vries, M. R., Quax, P. H. & Jukema, J. W. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 93, 922-927 (2007). (Pubitemid 47122040)
12. Schomig, A. et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1373-1380 (2007). (Pubitemid 47449734)
13. Smits, P. C. et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. The COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) trial. J. Am. Coll. Cardiol. 58, 11-18 (2011).
14. Stone, G. W. et al. Randomized comparison of everolimus- and paclitaxel-eluting stents 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J. Am. Coll. Cardiol. 58, 19-25 (2011).
15. Leon, M. B. et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol. 55, 543-554 (2010).
16. Rasmussen, K. et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 375, 1090-1099 (2010).
17. Silber, S., Windecker, S., Vranckx, P. & Serruys, P. W. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 377, 1241-1247 (2011).
18. Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35, 7S-14S (2003). (Pubitemid 36547910)
19. Ostojic, M. et al. The pharmacokinetics of biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter. Cardiovasc. Interv. 72, 901-908 (2008).
20. Ostojic, M. C. et al. The pharmacokinetics of biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK study. Eur. J. Clin. Pharmacol. 67, 389-398 (2011).
21. Vetrovec, G. W. et al. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. Catheter. Cardiovasc. Interv. 67, 32-37 (2006). (Pubitemid 43062605)
22. Hamilos, M. I. et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol. 51, 2123-2129 (2008). (Pubitemid 351721001)
23. Serruys, P. W. et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention 6, 195-205 (2010).
24. Hezi-Yamit, A. et al. Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. Comb. Chem. High Throughput Screen 12, 664-676 (2009).
25. Udipi, K. et al. The next generation Endeavor Resolute stent: role of the BioLinx polymer system. EuroIntervention 3, 137-139 (2007).
26. Talarico, G. P. et al. Exploring the possible clinical impact of polymer coating in DES technology: clinical outcome of consecutive patients treated by zotarolimus-eluting Endeavor stent and zotarolimus-eluting Resolute stent [abstract 42]. Eurointervention 7 (Suppl. M), M27 (2011).
27. Radeleff, B. et al. Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model. Cardiovasc. Intervent. Radiol. 31, 971-980 (2008).
28. Tamburino, C. et al. First-in-man 1-year clinical outcomes of the Catania coronary stent system with nanothin polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. JACC Cardiovasc. Interv. 2, 197-204 (2009).
29. La Manna, A. et al. One-year outcomes of CATANIA coronary stent system with nanothin polyzene-F in a real-world unselected population: assessment of the latest nonthrombogenic angioplasty stent 2 (ATLANTA-2) study. Eurointervention 6 (Suppl. H), H13 (2010).
30. Windecker, S. et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372, 1163-1173 (2008).
31. Byrne, R. A. et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur. Heart J. 30, 2441-2449 (2009).
32. Krucoff, M. W. et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J. Am. Coll. Cardiol. 51, 1543-1552 (2008). (Pubitemid 351512313)
33. Serruys, P. W. et al. LEADERS: 3-year follow-up from a prospective, randomized, trial of biolimus A9-eluting stents with a bioabsorbable polymer vs sirolimus-eluting stents with a durable polymer [abstract TCT-26]. J. Am. Coll. Cardiol. 56 (13 Suppl. 1), B9 (2010).
34. US National Institutes of Health. Test efficacy of biodegradable and permanent limus-eluting stents (ISAR-TEST6). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01068106 (2010).
35. Vorpahl, M., Finn, A. V., Nakano, M. & Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. Eurointervention 5 (Suppl. F), F28-F35 (2009).
36. van der Giessen, W. J. et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94, 1690-1697 (1996).
37. Lockwood, N. A. et al. In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings. J. Biomater. Sci. Polym. Ed. 21, 529-552 (2010).
38. Granada, J. F. et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ. Cardiovasc. Interv. 3, 257-266 (2010).
39. Byrne, R. A. et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 95, 1489-1494 (2009).
40. Byrne, R. A. et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc. Interv. 2, 291-299 (2009).
41. Tada, N. et al. Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv. 3, 174-183 (2010).
42. Costa, R. et al. De novo coronary lesions treated with the novel polymer-free Biolimus-A9 coated stents: Four- and twelve-month angiographic results from the prospective, randomized, multicenter BIOFREEDOM clinical trial [abstract 188]. EuroIntervention 7 (Suppl. M) (2011).
43. Adriaenssens, T. et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J. Am. Coll. Cardiol. 49, 1265-1271 (2007). (Pubitemid 46476843)
44. Byrne, R. A. et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents. J. Am. Coll. Cardiol. 55, 2536-2543 (2010).
45. Massberg, S. et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Trial. Circulation 124, 624-632 (2011).
46. Kipshidze, N. et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 44, 733-739 (2004). (Pubitemid 39099565)
47. Shirota, T., Yasui, H., Shimokawa, H. & Matsuda, T. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials 24, 2295-2302 (2003). (Pubitemid 36434048)
48. Co, M. et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am. Heart J. 155, 128-132 (2008). (Pubitemid 350234778)
49. Lee, Y. P. et al. Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: one year follow-up. EuroIntervention 5, 698-702 (2010).
50. Klomp, M., Beijk, M. A., Verouden, N. J., Tijssen, J. G. & de Winter, R. J. Design and rationale of the TRI-stent adjudication study (TRIAS) program. Am. Heart J. 158, 527-532 (2009).
51. Inoue, T. et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 115, 553-561 (2007). (Pubitemid 46226164)
52. Nakazawa, G. et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv. 3, 68-75 (2010).
53. US National Institutes of Health. Safety and effectiveness study of combo bio-engineered everolimus eluting stent (REMEDEE). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00967902 (2011).
54. Wöhrle, J. et al. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97, 1338-1342 (2011).
55. Garg, S. & Serruys, P. W. Coronary stents: looking forward. J. Am. Coll. Cardiol. 56, S43-S78 (2010).
56. Windecker, S. et al. Randomized comparison of a titanium-nitride-oxide- coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 111, 2617-2622 (2005). (Pubitemid 40740861)
57. Moschovitis, A. et al. Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. EuroIntervention 6, 63-68 (2010).
58. Karjalainen, P. P. et al. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. Ann. Med. 41, 599-607 (2009).
59. Karjalainen, P. P., Annala, A. P., Ylitalo, A., Vahlberg, T. & Airaksinen, K. E. Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int. J. Cardiol. 144, 42-46 (2010).
60. Karjalainen, P. P. A prospective, randomised and multicenter trial comparing a Titan-2 BAS and Xience-V stent: the BASE-ACS trial. Presented at EuroPCR 2011.
61. Pilgrim, T. et al. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. JACC Cardiovasc. Interv. 4, 672-682 (2011).
62. Lin, P. H. et al. Rheolytic pharmacomechanical thrombectomy in experimental chronic deep vein thrombosis: effect of L-arginine on thrombogenicity and endothelial vasomotor function. World J. Surg. 31, 664-675 (2007). (Pubitemid 46496253)
63. Fajadet, J. The future of bioactive stents: TiTAN OPTIMAX and VINCI Bio Active Eluting stent. Presented at EuroPCR 2011.
64. Meyers, S. R., Kenan, D. J., Khoo, X. & Grinstaff, M. W. Bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion. Biomacromolecules 12, 533-539 (2011).
65. Barber, T. A. et al. Peri-implant bone formation and implant integration strength of peptide-modified p(AAM-co-E G/AAC) interpenetrating polymer network-coated titanium implants. J. Biomed. Mater. Res. A. 80, 306-320 (2007). (Pubitemid 46122665)
66. Kastrati, A. et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103, 2816-2821 (2001). (Pubitemid 32550070)
67. Pache, J. et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol. 41, 1283-1288 (2003). (Pubitemid 36438988)
68. Stone, G. W. et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) trial. J. Am. Coll. Cardiol. 57, 1700-1708 (2011).
69. Kereiakes, D. J. et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J. Am. Coll. Cardiol. 56, 264-271 (2010).
70. Ormiston, J. A., Lefèvre, T., Grube, E., Allocco, D. & Dawkins, K. D. First human use of the Taxus Petal Paclitaxel-eluting bifurcation stent. EuroIntervention 6, 46-53 (2010).
71. Serruys, P. W. et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373, 897-910 (2009).
72. Erbel, R. et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicenter trial. Lancet 369, 1869-1875 (2007). (Pubitemid 46829357)
73. Onuma, Y. et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 6, 447-453 (2010).
74. Tanimoto, S. et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter. Cardiovasc. Interv. 70, 515-523 (2007). (Pubitemid 47597022)
75. Serruys, P. W. et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122, 2301-2312 (2010).
76. Gomez-Lara, J. et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190-1198 (2010).
77. Martinez, A. W. & Chaikof, E. L. Microfabrication and nanotechnology in stent design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 256-268 (2011).
78. Brito, L. & Amiji, M. Nanoparticulate carriers for the treatment of coronary restenosis. Int. J. Nanomedicine 2, 143-161 (2007). (Pubitemid 47215016)
79. Bhargava, B. et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter. Cardiovasc. Interv. 67, 698-702 (2006).
80. Luderer, F. et al. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J. Biomater. Appl. 25, 851-875 (2011).
81. Chorny, M. et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc. Natl. Acad. Sci. U. S. A. 107, 8346-8351 (2010).
82. Brito, L. A., Chandrasekhar, S., Little, S. R. & Amiji, M. M. Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed. Eng. Online 9, 56 (2010).
83. Takemoto, Y. et al. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. Arterioscler. Thromb. Vasc. Biol. 29, 857-862 (2009).
84. Lai, Y. M. et al. Synthetic pyrrole-imidazole polyamide inhibits expression of the human transforming growth factor-beta1 gene. J. Pharmacol. Exp. Ther. 315, 571-575 (2005).
85. Yao, E. H. et al. A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc. Res. 81, 797-804 (2009).
86. Yao, E. H. et al. Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension 52, 86-92 (2008).
87. Wang, Z. et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423, 555-560 (2003). (Pubitemid 36648581)
88. Bonta, P. I. et al. Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation 121, 2023-2032 (2010).
89. Pires, N. M. et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 115, 493-500 (2007). (Pubitemid 46184201)
90. O'Sullivan, J. F., Martin K. & Caplice, N. M. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". J. Am. Coll. Cardiol. 57, 383-389 (2011).
91. Versaci, F. et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J. Am. Coll. Cardiol. 40, 1935-1942 (2002). (Pubitemid 35425363)
92. US National Institutes of Health. Cortisone or drug-eluting stents (DES) as compared to bare-metal stents (BMS) to eliminate restenosis. ClinicalTrails.gov [online], http://clinicaltrials.gov/ct2/show/NCT00369356 (2011).
93. Pesarini, G. et al. Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans. Atherosclerosis 211, 242-248 (2010).
94. Gallo, R. et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99, 2164-2170 (1999). (Pubitemid 29196802)
95. Hausleiter, J. et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110, 790-795 (2004). (Pubitemid 39096005)
96. Rodriguez, A. E. et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention 5, 255-264 (2009).
97. Kufner, S. et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc. Interv. 2, 1142-1148 (2009).
98. Kubota, Y. et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest. Radiol. 30, 532-537 (1995).
99. Douglas, J. S. Jr. et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112, 2826-2832 (2005). (Pubitemid 41641677)
100. Lee, S. W. et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J. Am. Coll. Cardiol. 51, 1181-1187 (2008).
101. Jennings, D. L. & Kalus, J. S. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J. Clin. Pharmacol. 50, 415-421 (2010).
102. Kamal, A. K., Naqvi, I., Husain, M. R. & Khealani, B. A. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD008076. doi:10.1002/14651858.CD008076.pub2 (2011).
103. Hsueh, W. A. & Law, R. E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 21, 1891-1895 (2001). (Pubitemid 34219737)
104. Rosmarakis, E. S. & Falagas, M. E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am. Heart J. 154, 144-150 (2007). (Pubitemid 46920490)
105. Takagi, T. et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc. Interv. 2, 524-531 (2009).
106. Rathore, S. et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention 5, 841-846 (2010).
107. Dangas, G. D. et al. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 56, 1897-1907 (2010).
108. Nakazawa, G. et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. 57, 1314-1322 (2011).
109. Singh, I. M. et al. Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Catheter. Cardiovasc. Interv. 75, 338-342 (2010).
110. Mehran, R. et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100, 1872-1878 (1999). (Pubitemid 29511140)
111. Cosgrave, J. et al. Drug-eluting stent restenosis the pattern predicts the outcome. J. Am. Coll. Cardiol. 47, 2399-2404 (2006). (Pubitemid 43866381)
112. Solinas, E. et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am. J. Cardiol. 102, 311-315 (2008).
113. Leon, M. B. et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N. Engl. J. Med. 344, 250-256 (2001). (Pubitemid 32108529)
114. Waksman, R., Raizner, A. E., Yeung, A. C., Lansky, A. J. & Vandertie, L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 359, 551-557 (2002). (Pubitemid 34178435)
115. Holmes, D. R. Jr. et al. 5-year final results of the SISR (Sirolimus-Eluting Stents versus Vascular Brachytherapy for In-Stent Restenosis) trial [abstract 2904-9]. J. Am. Coll. Cardiol. 57 (Suppl. S), E1641 (2011).
116. Mauri, L. et al. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am. J. Cardiol. 90, 1079-1083 (2002). (Pubitemid 35339434)
117. Unterberg C. et al. Cutting balloon coronary angioplasty-initial clinical experience. Clin. Cardiol. 16, 660-664 (1993). (Pubitemid 23264088)
118. Ozaki, Y. et al. A quantitative coronary angiography-matched comparison between a prospective randomised multicenter cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. EuroIntervention 6, 400-406 (2010).
119. Park, S. J. et al. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ. J. 74, 1837-1845 (2010).
120. Scheller, B. et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355, 2113-2124 (2006). (Pubitemid 44749319)
121. Unverdorben, M. et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119, 2986-2994 (2009).
122. Joner, M. et al. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb. Hemost. 105, 864-872 (2011).
123. Hehrlein, C. et al. International first in man trial with a novel drug-eluting balloon in patients presenting with in-stent restenosis (PEPPER) [abstract 2904-8]. J. Am. Coll. Cardiol. 57 (Suppl. S) E1640 (2011).
124. Toelg, R. Comparison of bare metal and DES restenosis after treatment with a novel drug-eluting balloon - a subgroup analysis of the PEPPER first-in-man trial [abstract 267]. Eurointervention 7 (Suppl. M) (2011).
125. Wijns, W. et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 31, 2501-2555 (2010).
126. US National Institutes of Health. Treatment of drug-eluting stent (DES) in-stent restenosis with SeQuent® Please paclitaxel eluting percutaneous transluminal coronary angioplasty (PTCA) catheter. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00998439 (2011).
127. Alfonso, F. et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J. Am. Coll. Cardiol. 52, 1621-1627 (2008).
128. Holmes, D. R. Jr. et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 295, 1264-1273 (2006).
129. Stone, G. W. et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295, 1253-1263 (2006).
130. Singh, I. M. et al. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter. Cardiovasc. Interv. 76, 257-262 (2010).
131. Mehilli, J. et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J. Am. Coll. Cardiol. 55, 2710-2716 (2010).
132. Huang, S., Bjornsti, M. A. & Houghton, P. J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2, 222-232 (2003).
133. Orr, G. A., Verdier-Pinard, P., McDaid, H. & Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 22, 7280-7295 (2003). (Pubitemid 37487160)
134. Cosgrave, J. et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am. Heart J. 153, 354-359 (2007). (Pubitemid 46328767)
135. Costa, M. A. Treatment of drug-eluting stent restenosis. Am. Heart J. 153, 447-449 (2007). (Pubitemid 46440702)
136. Aminian, A., Kabir, T. & Eeckhout, E. Treatment of drug-eluting stent restenosis: an emerging challenge. Catheter. Cardiovasc. Interv. 74, 108-116 (2009).
137. Fishbein, I. et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc. Natl Acad. Sci. U. S. A. 103, 159-164 (2006). (Pubitemid 43076121)
138. Sharif, F. et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol. Ther. 16, 1674-1680 (2008).
139. Johnson, T. W. et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol. 25, 754-759 (2005). (Pubitemid 40463865)
140. Egashira, K. et al. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol. 27, 2563-2568 (2007). (Pubitemid 350158906)
141. Walter, D. H. et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110, 36-45 (2004). (Pubitemid 38885702)
142. Brasen, J. H. et al. Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. J. Am. Coll. Cardiol. 50, 2249-2253 (2007). (Pubitemid 350166823)